46 results about "Peptide formation" patented technology

The present invention provides conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.

In accordance with the present invention, it has been discovered that compounds which modulate the γ-secretase enzyme to make more of the shorter, less toxic and less aggregation-prone Aβ peptides (such as Aβ37 and Aβ38), while making less of the longer and more toxic and aggregation-prone AB peptides (such as AB40 and AB42) are useful as gamma-secretase modulators. In addition, these GSM compounds have further been discovered to have the selective property of modulating the formation of various AB peptides, while not inhibiting the overall activity of the γ-secretase enzyme. Thus, such compounds do not impede other critical functions of the γ-secretase enzyme, such as generating fragments from Notch that appear to control gene expression and cell differentiation. Therefore, in accordance with the present invention, there are provided screening assays useful for determining whether test compounds have GSM activity; accordingly, invention assays facilitate the identification of new gamma-secretase modulators. Such screening assays can be performed in a variety of ways, e.g., by assessing whether test compounds: lower the level of Aβ42 peptide, increase the level of Aβ37 and / or Aβ38 peptides, have substantially no effect on the processing of other γ-secretase substrates, and / or interact with at least one component of the γ-secretase complex. Also provided in accordance with the present invention are compounds having gamma-secretase modulatory activity as identified by any of the methods described herein; methods for producing formulations useful for modulating gamma-secretase activity, as well as the resulting formulations; methods for modulating gamma-secretase activity employing compounds identified according to invention methods and / or invention formulations, and the like.

The invention relates to a preparation method of a specific functional magnetic fluid; the preparation method is characterized in that water solution containing Fe<+3> and Fe<+2> is taken as raw material, the hydrolysis and the surface modification with NaOH water solution and poly-5-hydroxymethyl-furfural water solution in a supergravity field are carried out to obtain the surface modified magnetic fluid, the surface modified magnetic fluid is further coupled and combined with a synthesis oriented peptide to obtain the specific functional magnetic fluid with biocompatibility, biodegradability, bio-penetrating, magnetic response, nanoparticle property and the like; poly-5-hydroxymethyl-furfural is a soluble polymer organic matter which is obtained by polymerization of a biobased material 5-hydroxymethyl-furfural, the synthesis oriented peptide is generated by peptide formation reaction of various amino acids in an organic solvent under the action of a catalyst and at a certain temperature, and the oriented peptides with the different specific functions and the different uses can be obtained by controlling the types of the amino acids, the mixture ratio, the synthesis process conditions, etc.

The invention discloses a compound of PSCA (Prostate Stem Cell Antigen) polypeptide and nucleic acid, which is a granular compound obtained by the way that through positive and negative charge attraction, a PSCA gene recombination eukaryotic expression vector is packaged by fusogenic peptide formed by a positive ion peptide DNA (Deoxyribonucleic Acid) transport carrier and HLA-A2 limit CTL (Cytotoxic T Lymphocyte) epitope peptide PSCA 14-22. The preparation method comprises the steps that in buffer salt solution with pH of 7.2-7.6, the fusogenic peptide and the PSCA gene recombination eukaryotic expression vector are added according to a certain positive and negative charge ratio, are then mixed, and are left standing under room temperature for 0.5-1.5 hours to obtain the compound; the compound is not only combined with the advantages of DNA vaccine and epitope peptide vaccine, but also can imitate natural virus to directly 'infect' APC (Antigen Presenting Cell) and other immune cells, so as to stimulate strong CTL response in vivo. The compound is expected to break down selftolerance of tumour antigen, can be used to prepare prostate cancer therapeutic vaccine of more than 50 % of population in China, and has potential and good development and application prospect in the prostate cancer immunization therapy field.

The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or the second polypeptide by conventional technology.

The invention relates to a production method of N-tert-butoxycarbonyl-L-leucyl-L-methyl phenylalanine ((N-Boc-L-Leu-L-Phe-OMe). The method includes the following steps that a solution of 2-(7-enzotriazole oxide)-N, N', N'-tetramethylurea hexafluorophosphate (HATU) and a solution of N-tert-butoxycarbonyl-L-leucine (N-Boc-L-Leu) are continuously pumped into a first micro-reactor to produce activatedesters on-line, and then the on-line activated esters and a solution of L-phenylalanine methyl ester hydrochloride (L-Phe-OMe-HCl) are continuously pumped into a second micro-reactor for a peptide formation reaction. The method is used for producing N-tert-butoxycarbonyl-L-leucyl-L-methyl phenylalanine, the L-phenylalanine methyl ester hydrochloride as the raw material is completely converted under optimized conditions, and the yield of the product N-tert-butoxycarbonyl-L-leucyl-L-methyl phenylalanine is more than 99.5%. The method has the advantages that the reaction time is short, consumption of the raw materials is small, the yield is high and the process is continuous.

The invention discloses a single-domain antibody for recognizing a complex formed by an HLA-A2 molecule and an ITDQVPFSV short peptide. The single-domain antibody has an amino acid sequence shown in SEQ ID No.10 or SEQ ID No.11 or SEQ ID No.12. The invention also discloses a fusion protein obtained by fusing the single-domain antibody and a human-derived Fc protein. Experiments show that the single-domain antibody and fusion protein provided by the invention not only recognize the artificially synthesized HLA-A2 / ITDQVPFSV complex, but also can bind to the HLA-A2 / ITDQVPFSV complex processed bya natural antigen and expressed at the surfaces of tumor cells, and can be further developed into a related tumor treatment product.